Inotropic Agents Market to Grow Steadily with 11.6% CAGR, Propelled by Rising Heart Failure Incidences, Advanced Therapeutics, and Increasing R&D Investments

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Inotropic Agents Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $4.01 billion In 2028 At A CAGR Of 11.6% :

The inotropic agents market size has grown rapidly in recent years. It will grow from $2.32 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to education and awareness initiatives, expansion of cardiac treatment options, development of safer agents, improved patient outcomes, regulatory approvals.

The inotropic agents market size is expected to see rapid growth in the next few years. It will grow to $4.01 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to growing cardiovascular disease burden, advancements in drug delivery systems, personalized medicine approach, increasing research funding, demand for combination therapies. Major trends in the forecast period include patient education and awareness, targeting cardiomyopathies, focus on heart failure management, combination therapies, improved safety profiles.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=10711&type=smp

Inotropic Agents Market Major Segments
The inotropic agents market covered in this report is segmented -

1) By Type: Positive Inotropic Drugs, Negative Inotropic Drugs, Other Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Indication: Heart Attack, Heart Failure, Angina, Arrhythmia, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End User: Hospital, Homecare, Specialty Centers, Other End Users

Key Driver - Surging Cardiovascular Diseases Propel Growth In The Inotropic Agent Market

The surge in the prevalence of cardiovascular diseases is driving the inotropic agent market. Cardiovascular diseases (CVDs) refer to diseases of the vascular system and heart functioning. Inotropic agents are used in the treatment of cardiovascular diseases to improve the contractility and function of the heart, tackle cardiac shock, and slow the heart rate as they help the heart contract more powerfully, thereby increasing blood flow. So this helps boost the inotropic agent market. For instance, in October 2022, according to the reports shared by the Centers for Disease Control and Prevention, a US-based government agency, heart diseases were the leading cause of death in the US. About 697,000 people died from heart disease in 2020, which was roughly 1 in every 5 deaths. About 20.1 million adults were suffering from coronary artery disease. Each year, about 805,000 people in the US suffer from a heart attack. Furthermore, in August 2022, according to the American College of Cardiology, a US-based nonprofit medical association, the risk of stroke was expected to increase by 33.8 percent to 15 million from 2025 to 2060. Therefore, the surge in the prevalence of cardiovascular diseases is propelling the inotropic agent market forward.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=10711&type=smp

Prominent Trend - Bristol-Myers Squibb's Mavacamten Receives Fda Approval, Setting A Trend In The Inotropic Agents Market

Drug approval is a key trend gaining popularity in the inotropic agents market. Major companies in the market are developing innovative new products and drugs to sustain their position in the market. For instance, in April 2022, Bristol-Myers Squibb., a US-based pharmaceutical developer and manufacturer, received regulatory approval for Camzyos™ (mavacamten) from the U.S. Food and Drug Administration (FDA), a US-based national public health agency and regulator. It is used in the treatment of class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. This medication works by inhibiting the excessive contraction of the heart muscle. It is a selective inhibitor of cardiac myosin, a protein involved in muscle contraction. It is typically prescribed to individuals who have symptomatic obstructive HCM and have not adequately responded to other treatment options, such as beta-blockers or calcium channel blockers.

Inotropic Agents Market Players
Major companies operating in the inotropic agents market report are Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH, AstraZeneca plc, Johnson & Johnson, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Ltd., Eli Lilly And Company, Sanofi S.A., Baxter International Inc., Hikma Pharmaceuticals plc, Sun Pharmaceuticals Industries Ltd., Cadila Pharmaceuticals Ltd., AbbVie Inc., Allergan plc, Amgen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Fresenius Kabi AG, Genentech Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Regeneron Pharmaceuticals Inc., Roche Holding AG, BioNTech SE

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the inotropic agents market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global inotropic agents market report during the forecast period. The regions covered in the inotropic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Inotropic Agents Market Report Structure
3. Inotropic Agents Market Trends And Strategies
4. Inotropic Agents Market - Macro Economic Scenario
5. Inotropic Agents Market Size And Growth
…..
27. Inotropic Agents Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.